InsiderTrades.com logo
Allison Dorval net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Allison Dorval Biography and Net Worth

CFO of Verve Therapeutics

Allison Dorval is the chief financial officer at Verve Therapeutics. She has more than 25 years of leadership experience in finance, accounting and investor relations, including 15 in the life sciences industry. Prior to joining Verve, Allison served as chief financial officer at Voyager Therapeutics. She has also served as vice president and controller of Juniper Pharmaceuticals and as a consultant at Danforth Advisors. She has held several leadership roles at Insulet Corporation, including chief financial officer. Earlier in her career, she served in corporate finance positions with iBasis, Inc. and Digitas Inc. Allison is a member of the Board of Directors at Aerovate Therapeutics and Puma Biotechnology. 

Allison obtained a B.S. in Business Administration from the University of Vermont. She is a certified public accountant and began her career at PwC.

What is Allison Dorval's net worth?

The estimated net worth of Allison Dorval is at least $839.09 thousand as of June 13th, 2025. Ms. Dorval owns 75,390 shares of Verve Therapeutics stock worth more than $839,091 as of December 5th. This net worth approximation does not reflect any other investments that Ms. Dorval may own. Additionally, Ms. Dorval receives a salary of $711,760.00 as CFO at Verve Therapeutics. Learn More about Allison Dorval's net worth.

How old is Allison Dorval?

Ms. Dorval is currently 48 years old. There are 5 older executives and no younger executives at Verve Therapeutics. The oldest executive at Verve Therapeutics is Dr. Barry S. Ticho FACC, M.D., Ph.D., Co-Founder, who is 63 years old. Learn More on Allison Dorval's age.

What is Allison Dorval's salary?

As the CFO of Verve Therapeutics, Inc., Ms. Dorval earns $711,760.00 per year. There are 2 executives that earn more than Ms. Dorval. The highest earning executive at Verve Therapeutics is Dr. Sekar Kathiresan M.D., Co-Founder, CEO & Director, who commands a salary of $973,250.00 per year. Learn More on Allison Dorval's salary.

How do I contact Allison Dorval?

The corporate mailing address for Ms. Dorval and other Verve Therapeutics executives is , , . Verve Therapeutics can also be reached via phone at 617-603-0070 and via email at [email protected]. Learn More on Allison Dorval's contact information.

Has Allison Dorval been buying or selling shares of Verve Therapeutics?

Allison Dorval has not been actively trading shares of Verve Therapeutics within the last three months. Most recently, Allison Dorval sold 3,350 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $4.15, for a transaction totalling $13,902.50. Following the completion of the sale, the chief financial officer now directly owns 13,280 shares of the company's stock, valued at $55,112. Learn More on Allison Dorval's trading history.

Who are Verve Therapeutics' active insiders?

Verve Therapeutics' insider roster includes Burt Adelman (Director), Andrew Ashe (Insider), Andrew Bellinger (Insider), Allison Dorval (CFO), Sekar Kathiresan (CEO), and Joan Nickerson (Senior Vice President, Human Resources and Facilities). Learn More on Verve Therapeutics' active insiders.

Are insiders buying or selling shares of Verve Therapeutics?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 6,127 shares worth more than $25,427.05. The most recent insider tranaction occured on April, 2nd when insider Joan Nickerson sold 2,777 shares worth more than $11,524.55. Insiders at Verve Therapeutics own 19.3% of the company. Learn More about insider trades at Verve Therapeutics.

Information on this page was last updated on 4/2/2025.

Allison Dorval Insider Trading History at Verve Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2025Sell3,350$4.15$13,902.5013,280View SEC Filing Icon  
11/29/2023Sell554$11.45$6,343.304,060View SEC Filing Icon  
11/29/2022Sell554$22.10$12,243.402,186View SEC Filing Icon  
See Full Table

Allison Dorval Buying and Selling Activity at Verve Therapeutics

This chart shows Allison Dorval's buying and selling at Verve Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verve Therapeutics Company Overview

Verve Therapeutics logo
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $11.13
Low: $11.13
High: $11.13

50 Day Range

MA: $11.13
Low: $10.91
High: $11.38

2 Week Range

Now: $11.13
Low: $2.86
High: $11.40

Volume

N/A

Average Volume

3,941,096 shs

Market Capitalization

$992.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.23